angiotensin-receptor blockers

Candesartan - Irbesartan - Losartan - Telmisartan - Valsartan      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathCardiovascular death

acute myocardial infarction

losartan
OPTIMAAL, 2002     LosartanCaptoprilLow risk of bias suggesting 15%
valsartan
VALIANT (valsartan+capropril), 2003     Valsartan+ACE inhibitor ACE inhibitor onlyLow risk of bias negative0%
VALIANT (valsartan alone), 2003     ValsartanCaptoprilLow risk of bias negative0%

diabetes type 2

irbesartan
IPDM (150mg), 2001     irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias suggesting4%
losartan
RENAAL, 2001     losartanplaceboLow risk of bias suggesting2%
olmesartan
ROADMAP, 2010        NCTolmesartanplaceboLow risk of bias suggesting 72%396%
ORIENT    NCTolmesartanplaceboLow risk of bias negative-4%236%

heart failure

candesartan
ARCH-J, 2003     candesartanplaceboLow risk of bias -
CHARM-Alternative, 2003     candesartanplaceboLow risk of bias suggesting -13%
Mitrovic et al., 2003     candesartanplaceboLow risk of bias suggesting-37%
SPICE, 2000     candesartanplaceboLow risk of bias negative2%
STRETCH, 1999     candesartanplaceboLow risk of bias -
CHARM preserved, 2003   candesartanplaceboLow risk of bias -
CHARM-Added, 2003       candesartan+ACE inhibitorACE inhibitor onlyLow risk of bias negative
RESOLVD association, 1999     candesartan+ACE inhibitorACE inhibitor onlyExploratory negative
RESOLVD (candesartan alone), 1999     candesartanenalaprilLow risk of bias negative
irbesartan
I-PRESERVE (McMurray), 2008      NCTibesartanplaceboLow risk of bias negative2%3%
Tonkon et al., 2000   irbesartan+ACE inhibitorACE inhibitor onlyLow risk of bias -
losartan
HEAAL, 2009        NCTlosartan 150mglosartan 50mgLow risk of bias suggesting-6%
Losartan Phase III International, 1996       losartanplaceboLow risk of bias suggesting-83%
Losartan Phase III U.S., 1995     losartanplaceboLow risk of bias negative-52%
Hamroff et al., 1999     losartan+ACE inhibitorACE inhibitor onlyLow risk of bias -
ELITE, 1997       losartancaptoprilLow risk of bias negative-47%
ELITE II, 2000     losartancaptoprilLow risk of bias -
Dickstein et al., 1995     losartanenalaprilLow risk of bias -
Lang et al., 1997     losartanenalaprilLow risk of bias -
Losartan phase II S, 1996     losartanenalaprilLow risk of bias -
losartan phase II US, 1996     losartanenalaprilLow risk of bias -
telmisartan
REPLACE, 2001     telmisartanenalaprilLow risk of bias -
valsartan
VALIDD, 2007    NCTvalsartanno valsartanLow risk of bias negative
Mazayev et al. (vs placebo), 1998     valsartanplaceboLow risk of bias -
V-HeFT, 1999     valsartan+ACE inhibitorACE inhibitor onlyLow risk of bias negative
Val-HeFT, 2001     valsartan+ACE inhibitorACE inhibitor onlyLow risk of bias suggesting 2%
HEAVEN, 2002     valsartanenalaprilLow risk of bias -
Mazayev et al. (vs lisinopril, 1998     valsartanLisinoprilExploratory -

hypertension

candesartan
Takahashi, 2006     candesartancontrolExploratory negative-100%
E-COST, 2005     candesartanconventional treatmentRisk of bias suggesting-6%+Infini%
E-COST-R, 2005     candesartanconventional treatmentRisk of bias negative4%4%
HIJ-CREATE, 2009     candesartanconventional treatmentRisk of bias suggesting17%12%
SCOPE, 2003   candesartanplaceboLow risk of bias negative-3%-5%
HIJ-CREATE, 2009     Candesartanusual careRisk of bias -
CASE-J, 2008     candesartanamlodipineRisk of bias suggesting-15%
ALPINE, 2003   candesartanhydrochlorothiazideLow risk of bias suggesting
captopril
VALIANT/Val+Cap, 2003       Valsartan + captoprilCaptoprilLow risk of bias negative-1%0%
irbesartan
IDNT (irbesartan vs pbo), 2001       irbesartanplaceboLow risk of bias negative-8%11%
IRMA 2, 2001     irbesartanplaceboLow risk of bias negative13%
losartan
RENAAL, 2001     losartanplaceboLow risk of bias -
LIFE, 2002     losartanatenololLow risk of bias suggesting -11%-13%
ELITE, 1997     LosartanCaptoprilLow risk of bias suggesting-44%-47%
ELITE-II, 2000     LosartanCaptoprilLow risk of bias negative12%15%
OPTIMAAL, 2001     LosartanCaptoprilRisk of bias negative 11%15%
ramipril
ONTARGET/Tel+Ram, 2008     Telmisartan + ramiprilRamiprilLow risk of bias negative6%4%
telmisartan
PROPHESS, 2008      NCTtelmisartanplaceboLow risk of bias negative2%-15%
DETAIL, 2004     TelmisartanEnalaprilLow risk of bias negative8%63%
ONTARGET/Tel, 2008     TelmisartanRamiprilLow risk of bias negative-2%0%
valsartan
VALIANT/Val, 2003       ValsartanCaptoprilLow risk of bias negative2%0%

miscellaneous

candesartan
Takahashi, 2006     candesartancontrolExploratory negative-100%
E-COST, 2005     candesartanconventional treatmentRisk of bias suggesting-6%+Infini%
E-COST-R, 2005     candesartanconventional treatmentRisk of bias negative4%4%
HIJ-CREATE, 2009     candesartanconventional treatmentRisk of bias suggesting17%12%
SCOPE, 2003   candesartanplaceboLow risk of bias negative-3%-5%
TROPHY, 2006      NCTcandesartanplaceboLow risk of bias suggesting
CASE-J, 2008     candesartanamlodipineRisk of bias suggesting-15%
ALPINE, 2003   candesartanhydrochlorothiazideLow risk of bias suggesting
irbesartan
IDNT (irbesartan vs pbo), 2001       irbesartanplaceboLow risk of bias negative-8%11%
IRMA 2, 2001     irbesartanplaceboLow risk of bias negative13%
losartan
RENAAL, 2001     losartanplaceboLow risk of bias -
LIFE, 2002     losartanatenololLow risk of bias suggesting -11%-13%
olmesartan
ROADMAP, 2010        NCTolmesartanplaceboLow risk of bias suggesting 72%396%
ORIENT    NCTolmesartanplaceboLow risk of bias negative-4%236%
ramipril
ONTARGET (association vs ramipril), 2008    NCTtelmisartan + ramiprilramiprilLow risk of bias negative 6%4%
ONTARGET (association vs telmisartan), 2008    NCTtelmisartan + ramipriltelmisartanLow risk of bias suggesting 8%4%
telmisartan
TRANSCEND, 2008    NCTtelmisartanplaceboLow risk of bias suggesting5%2%
PROPHESS, 2008      NCTtelmisartanplaceboLow risk of bias negative2%-15%
ONTARGET (telmisartan alone), 2008      NCTtelmisartanramiprilLow risk of bias suggesting -2%0%

patients at high risk for cardiovascular events

candesartan
SCOPE, 2003   candesartanplaceboLow risk of bias negative-3%-5%
losartan
RENAAL, 2001     losartanplaceboLow risk of bias -
LIFE, 2002     losartanatenololLow risk of bias suggesting -11%-13%
ramipril
ONTARGET (association vs ramipril), 2008    NCTtelmisartan + ramiprilramiprilLow risk of bias negative 6%4%
ONTARGET (association vs telmisartan), 2008    NCTtelmisartan + ramipriltelmisartanLow risk of bias suggesting 8%4%
telmisartan
TRANSCEND, 2008    NCTtelmisartanplaceboLow risk of bias suggesting5%2%
PROPHESS, 2008      NCTtelmisartanplaceboLow risk of bias negative2%-15%
ONTARGET (telmisartan alone), 2008      NCTtelmisartanramiprilLow risk of bias suggesting -2%0%